A citation-based method for searching scientific literature

E J Lewis, L G Hunsicker, W R Clarke, T Berl, M A Pohl, J B Lewis, E Ritz, R C Atkins, R Rohde, I Raz. N Engl J Med 2001
Times Cited: 4123







List of co-cited articles
820 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
B M Brenner, M E Cooper, D de Zeeuw, W F Keane, W E Mitch, H H Parving, G Remuzzi, S M Snapinn, Z Zhang, S Shahinfar. N Engl J Med 2001
83

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
44


Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
George L Bakris, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M Ruilope, Peter Rossing, Peter Kolkhof, Christina Nowack, Patrick Schloemer, Amer Joseph,[...]. N Engl J Med 2020
492
40

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
39

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
25

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
22

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
Bertram Pitt, Gerasimos Filippatos, Rajiv Agarwal, Stefan D Anker, George L Bakris, Peter Rossing, Amer Joseph, Peter Kolkhof, Christina Nowack, Patrick Schloemer,[...]. N Engl J Med 2021
193
22

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
H H Parving, H Lehnert, J Bröchner-Mortensen, R Gomis, S Andersen, P Arner. N Engl J Med 2001
20

Diabetic Kidney Disease: Challenges, Progress, and Possibilities.
Radica Z Alicic, Michele T Rooney, Katherine R Tuttle. Clin J Am Soc Nephrol 2017
858
20

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
20

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Hiddo J L Heerspink, Hans-Henrik Parving, Dennis L Andress, George Bakris, Ricardo Correa-Rotter, Fan-Fan Hou, Dalane W Kitzman, Donald Kohan, Hirofumi Makino, John J V McMurray,[...]. Lancet 2019
252
20

Combined angiotensin inhibition for the treatment of diabetic nephropathy.
Linda F Fried, Nicholas Emanuele, Jane H Zhang, Mary Brophy, Todd A Conner, William Duckworth, David J Leehey, Peter A McCullough, Theresa O'Connor, Paul M Palevsky,[...]. N Engl J Med 2013
685
20

Liraglutide and Renal Outcomes in Type 2 Diabetes.
Johannes F E Mann, David D Ørsted, Kirstine Brown-Frandsen, Steven P Marso, Neil R Poulter, Søren Rasmussen, Karen Tornøe, Bernard Zinman, John B Buse. N Engl J Med 2017
599
18

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
18

Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
Hans-Henrik Parving, Barry M Brenner, John J V McMurray, Dick de Zeeuw, Steven M Haffner, Scott D Solomon, Nish Chaturvedi, Frederik Persson, Akshay S Desai, Maria Nicolaides,[...]. N Engl J Med 2012
822
17

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
16

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
Katherine R Tuttle, Mark C Lakshmanan, Brian Rayner, Robert S Busch, Alan G Zimmermann, D Bradley Woodward, Fady T Botros. Lancet Diabetes Endocrinol 2018
258
16

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
14

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
14


Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
George L Bakris, Rajiv Agarwal, Juliana C Chan, Mark E Cooper, Ron T Gansevoort, Hermann Haller, Giuseppe Remuzzi, Peter Rossing, Roland E Schmieder, Christina Nowack,[...]. JAMA 2015
352
12



Avosentan for overt diabetic nephropathy.
Johannes F E Mann, Damian Green, Kenneth Jamerson, Luis M Ruilope, Susan J Kuranoff, Thomas Littke, Giancarlo Viberti. J Am Soc Nephrol 2010
332
11

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Ofri Mosenzon, Stephen D Wiviott, Avivit Cahn, Aliza Rozenberg, Ilan Yanuv, Erica L Goodrich, Sabina A Murphy, Hiddo J L Heerspink, Thomas A Zelniker, Jamie P Dwyer,[...]. Lancet Diabetes Endocrinol 2019
336
11

Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.
Andrew S Levey, Ron T Gansevoort, Josef Coresh, Lesley A Inker, Hiddo L Heerspink, Morgan E Grams, Tom Greene, Hocine Tighiouart, Kunihiro Matsushita, Shoshana H Ballew,[...]. Am J Kidney Dis 2020
177
10

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.
P Ruggenenti, A Perna, G Gherardi, G Garini, C Zoccali, M Salvadori, F Scolari, F P Schena, G Remuzzi. Lancet 1999
667
10

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.
Rajiv Agarwal, Peter Kolkhof, George Bakris, Johann Bauersachs, Hermann Haller, Takashi Wada, Faiez Zannad. Eur Heart J 2021
103
10

Kidney disease and increased mortality risk in type 2 diabetes.
Maryam Afkarian, Michael C Sachs, Bryan Kestenbaum, Irl B Hirsch, Katherine R Tuttle, Jonathan Himmelfarb, Ian H de Boer. J Am Soc Nephrol 2013
597
10

A new equation to estimate glomerular filtration rate.
Andrew S Levey, Lesley A Stevens, Christopher H Schmid, Yaping Lucy Zhang, Alejandro F Castro, Harold I Feldman, John W Kusek, Paul Eggers, Frederick Van Lente, Tom Greene,[...]. Ann Intern Med 2009
10

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Christopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Urszula Masiukiewicz, Bernard Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino,[...]. N Engl J Med 2020
517
9

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Fady T Botros, Matthew C Riddle, Lars Rydén,[...]. Lancet 2019
240
9

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.
Rajiv Agarwal, Patrick Rossignol, Alain Romero, Dahlia Garza, Martha R Mayo, Suzette Warren, Jia Ma, William B White, Bryan Williams. Lancet 2019
138
9

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.
Gerasimos Filippatos, Stefan D Anker, Rajiv Agarwal, Bertram Pitt, Luis M Ruilope, Peter Rossing, Peter Kolkhof, Patrick Schloemer, Ingo Tornus, Amer Joseph,[...]. Circulation 2021
100
9

Diabetic kidney disease: a report from an ADA Consensus Conference.
Katherine R Tuttle, George L Bakris, Rudolf W Bilous, Jane L Chiang, Ian H de Boer, Jordi Goldstein-Fuchs, Irl B Hirsch, Kamyar Kalantar-Zadeh, Andrew S Narva, Sankar D Navaneethan,[...]. Diabetes Care 2014
540
9

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Jackson T Wright, George Bakris, Tom Greene, Larry Y Agodoa, Lawrence J Appel, Jeanne Charleston, DeAnna Cheek, Janice G Douglas-Baltimore, Jennifer Gassman, Richard Glassock,[...]. JAMA 2002
9

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Brendon L Neuen, Tamara Young, Hiddo J L Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W Mahaffey, David M Charytan, David C Wheeler, Clare Arnott,[...]. Lancet Diabetes Endocrinol 2019
371
9

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
Kenneth W Mahaffey, Meg J Jardine, Severine Bompoint, Christopher P Cannon, Bruce Neal, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris,[...]. Circulation 2019
148
8

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
8

Efficacy and safety of benazepril for advanced chronic renal insufficiency.
Fan Fan Hou, Xun Zhang, Guo Hua Zhang, Di Xie, Ping Yan Chen, Wei Ru Zhang, Jian Ping Jiang, Min Liang, Guo Bao Wang, Zheng Rong Liu,[...]. N Engl J Med 2006
447
8



Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial.
Sadayoshi Ito, Naoki Kashihara, Kenichi Shikata, Masaomi Nangaku, Takashi Wada, Yasuyuki Okuda, Tomoko Sawanobori. Clin J Am Soc Nephrol 2020
60
13

Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.
Peter Kolkhof, Martina Delbeck, Axel Kretschmer, Wolfram Steinke, Elke Hartmann, Lars Bärfacker, Frank Eitner, Barbara Albrecht-Küpper, Stefan Schäfer. J Cardiovasc Pharmacol 2014
184
8

A Randomized Trial of Intensive versus Standard Blood-Pressure Control.
Jackson T Wright, Jeff D Williamson, Paul K Whelton, Joni K Snyder, Kaycee M Sink, Michael V Rocco, David M Reboussin, Mahboob Rahman, Suzanne Oparil, Cora E Lewis,[...]. N Engl J Med 2015
8

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen, Mark E Cooper, Steven E Kahn, Nikolaus Marx, John H Alexander, Michael Pencina, Robert D Toto, Christoph Wanner,[...]. JAMA 2019
551
8

Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
George L Bakris, Bertram Pitt, Matthew R Weir, Mason W Freeman, Martha R Mayo, Dahlia Garza, Yuri Stasiv, Rezi Zawadzki, Lance Berman, David A Bushinsky. JAMA 2015
263
8

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.
Hertzel C Gerstein, Naveed Sattar, Julio Rosenstock, Chinthanie Ramasundarahettige, Richard Pratley, Renato D Lopes, Carolyn S P Lam, Nardev S Khurmi, Laura Heenan, Stefano Del Prato,[...]. N Engl J Med 2021
133
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.